Zepbound’s clinical tests in obstructive sleep apnea showed improvement in breathing disruptions that were accompanied by reductions in body weight. The new approval gives the Eli Lilly medicine the opportunity to become a blockbuster seller in yet another indication.
The post Eli Lilly’s Zepbound Becomes First FDA-Approved Drug Therapy for Sleep Apnea appeared first on MedCity News.
Leave a comment